

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*

**MINGYUAN MEDICARE DEVELOPMENT COMPANY LIMITED**

**銘源醫療發展有限公司\***

*(Incorporated in Bermuda with limited liability)*

**(Stock code: 0233)**

**INSIDE INFORMATION**

This announcement is made by Mingyuan Medicare Development Company Limited (the “**Company**”) pursuant to Rule 13.09(2)(a) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”) and Inside Information Provisions under Part XIVA of the Securities and Futures Ordinance.

Reference is made to the announcements of the Company dated 1 December 2016 and 10 October 2017 (the “**Announcements**”) regarding the two separate civil complaints in the People’s Republic of China (the “**PRC**”) made by the two wholly indirectly owned subsidiaries, namely SHMY Biochips and Shanghai HealthDigit, against their current legal representatives Yao and Iu.

In this announcement, unless otherwise specified, the same abbreviations and descriptions used in the Announcements are adopted.

In relation to the civil complaint made by SHMY Biochips, the Company, under the advice of its PRC lawyer, made an appeal against the judgment handed down on 28 September 2017 (the “**28/9 Judgment**”). The appeal was heard by the Shanghai No.1 Intermediate People’s Court (the “**Court**”) on 21 December 2017 and judgment was delivered on 16 January 2018 (the “**16/1 Judgment**”).

In the 16/1 Judgment, the Court ruled that the burden to prove the relevant licences of SHMY Biochips being in Yao’s possession and control was on SHMY Biochips. Given that SHMY Biochips was unable to produce evidence to prove that, the Court upheld the 28/9 Judgment. The Company is now seeking advice from its PRC lawyer on the matter and will inform the shareholders of further development of the matter in due course.

*\* For identification purpose only*

Trading in shares of the Company will remain suspended.

By Order of the Board  
**Mingyuan Medicare Development Company Limited**  
**LAM Ping Cheung**  
*Chairman*

Hong Kong, 29 January 2018

*As at the date of this announcement, the Board comprises (i) Mr. Lam Ping Cheung and Mr. Hui Yip Wing as executive Directors; (ii) Dr. Wong Peter Kai-hong as non-executive Director; (iii) Ms. Chan Mee Sze, Mr. Lam Suk Ping, Mr. Cheung Chi Ming and Ms. Fan Stephanie Winnie as independent non-executive Directors.*